设为首页 加入收藏

TOP

TRISENOX 1 mg/ml, concentrate for solution for infusionPatie
2014-10-22 19:03:32 来源: 作者: 【 】 浏览:416次 评论:0

For doctors

 

What is it and how is it used?

TRISENOX is used in patients with acute promyelocytic leukaemia (APL) whose disease has not responded to other therapies. APL is a unique type of myeloid leukaemia, a disease in which abnormal white blood cells and abnormal bleeding and bruising occur.

What do you have to consider before using it?

TRISENOX must be injected under the supervision of a physician experienced in the treatment of acute leukaemias.

Do not use TRISENOX

Take special care with TRISENOX
Please tell your doctor immediately if you have any of the following symptoms: shortness of breath, fever, sudden weight gain, fainting, water retention or palpitations (strong heartbeat you can feel in your chest). .
Your doctor must check your blood to be sure that you do not have low amounts of potassium or magnesium before your first dose of TRISENOX. You should also have a 12-lead electrocardiogram performed before your first dose. Blood tests should be repeated twice weekly while you are receiving TRISENOX. In addition, you will receive electrocardiograms twice weekly. If you are at risk for a certain type of abnormal heart rhythm (e.g. torsade de pointes or QTc prolongation) your heart will be monitored continuously.
You must tell your doctor if you have impaired kidney or liver function.

Using other medicines
Please tell your doctor if you are taking any of various types of medicines which could cause a change in the rhythm of your heartbeat. These include:

Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription.

Using TRISENOX with food and drink

Pregnancy

Ask your doctor or pharmacist for advice before taking any medicine. TRISENOX may cause harm to the foetus when used by pregnant women. If you are able to become pregnant, you must use effective birth control during treatment with TRISENOX. If you are pregnant or you become pregnant during the treatment with TRISENOX, you must ask your doctor for advice.

Men should also use effective contraception during treatment with TRISENOX.

Breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine. Arsenic will be present in the milk of TRISENOX patients who are breast-feeding. Because of the potential for serious side-effects in nursing infants from TRISENOX, do not breast-feed while on TRISENOX.

Driving and using machines

The effect of TRISENOX on your ability to drive is not known. If you experience discomfort or if you feel unwell after a TRISENOX injection, you should wait until the symptoms go away before driving or using machines.

Important information about some of the ingredients of TRISENOX

Trisenox contains less than 1 mmol sodium (23 mg) per dose i.e. essentially ‘sodium-free’.

How is it used?

Your doctor will dilute TRISENOX with 100 to 250 ml of glucose 50 mg/ml (5%) injection, or sodium chloride 9 mg/ml (0.9%) injection.

Your doctor will infuse TRISENOX through a tube into a blood vessel over 1-2 hours, but the infusion may last longer if side-effects like flushing and dizziness occur.

Your doctor will give you TRISENOX once every day as a single infusion each day. In your first treatment cycle, you may be treated every day up to 50 days at most, or until your doctor determines that your disease is better. If your disease responds to TRISENOX, you will be given a second treatment cycle of 25 doses, one infusion every weekday for 5 weeks. Your doctor will decide exactly how long you must continue on therapy with TRISENOX.

Each TRISENOX ampoule must be used only once and does not contain any preservatives. Unused portions of each ampoule must be discarded properly.

Do not save any unused portions for later use.

TRISENOX must not be mixed with, or infused through the same tube with other medicinal products.

If your doctor gives you more TRISENOX than he/she should

You may experience convulsions, muscle weakness and confusion. If this happens, treatment with TRISENOX must be stopped immediately and your doctor will treat the arsenic overdose.

What are possible side effects?

Like all medicines, TRISENOX can have side effects.

While on treatment with TRISENOX, you may experience some of the following reactions: common side effects (greater than or equal to 1 in 100 but less than 1 in 10): fatigue (weariness), increased blood sugar, shortness of breath, cough, headache.
uncommon side effects (greater than or equal to 1 in 1000 but less than 1 in 100): increased white blood cell count, Herpes zoster, pneumonia, sepsis, anaemia, dehydration, confusion, blurry vision, cardiac failure, hypotension, pneumonitis, chills, renal failure, increased weight, nausea, vomiting, diarrhoea, stomach ache, oedema (water retention), rash or itching, change in your heart rhythm or dizziness.
Frequency unknown: decreased blood cell counts, a syndrome including fever, together with difficulty in breathing, coughing and chest pain. If you experience these symptoms, you should inform your doctor immediately.

Other side effects not mentioned above may also occur in some patients.

Tell your doctor immediately if you experience shortness of breath, fever, sudden weight gain, water retention, fainting or palpitations (strong heartbeat you can feel in your chest).

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children

Do not use after the expiry date stated on the ampoule label.
Do not freeze

After dilution, if not used immediately, in-use storage times and conditions before use are the responsibility of your doctor and would normally not be longer than 24 hours at 2ºC – 8ºC, unless dilution has taken place in a sterile environment.

Do not use TRISENOX if you notice foreign particulate matter or if discolouration is present.

↑ back to table of contents ↑

For doctors

What is it?

Trisenox is a concentrate that is made up into a solution for infusion (drip into a vein). It contains the active substance arsenic trioxide.

What is it used for?

Trisenox is used to treat adults (aged 18 years or over) with acute promyelocytic leukaemia (APL), a rare form of leukaemia (cancer of the white blood cells). APL is caused by a genetic ‘translocation’ (when there is a swap of genes between two chromosomes). The translocation affects the way the white blood cells grow, and they lack the ability to use retinoic acid (vitamin A). Patients with APL are normally treated with retinoids (substances derived from vitamin A). Trisenox is used when patients have not responded to treatment with retinoids and anticancer medicines, or when their disease has come back after this type of treatment.

Because the number of patients with APL is low, the disease is considered ‘rare’, and Trisenox was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 October 2000.

The medicine can only be obtained with a prescription.

How is it used?

Trisenox treatment should be supervised by a doctor who has experience in the management of patients with acute leukaemias.

Trisenox is given every day until there are signs that the treatment is working (when the bone marrow does not contain any leukaemia cells). If this does not happen by day 50, treatment should be stopped.

The first treatment is then consolidated, three to four weeks later, by giving Trisenox once a day for five days, followed by a two-day break, repeated for five weeks.

Trisenox is given as an infusion lasting one to two hours, but this may be increased to four hours if there are side effects caused by the infusion.

How does it work?

The active substance in Trisenox, arsenic trioxide, is a chemical that has been used in medicines for many years, including for the treatment of leukaemia. The way it works in this disease is not completely understood. It is thought to prevent the production of DNA, which is necessary for leukaemia cells to grow.

How has it been studied?

Trisenox has been examined in two studies involving a total of 52 patients with APL who had been previously treated with an anthracycline (a type of anticancer medicine) and a retinoid. Forty-five of the patients in the studies were adults. Trisenox was not compared with any other medicine in either study. The main measure of effectiveness was the number of patients who had complete remission. This is when there are no more leukaemia cells in the bone marrow and the levels of platelets and white blood cells in the blood have recovered.

What benefits has it shown during the studies?

Looking at the results of the two studies together, 87% of the patients had complete remission (45 out of 52). On average, it took 57 days for the patients to reach complete remission.

What is the risk associated?

The most common side effects with Trisenox (seen in between 1 and 10 patients in 100) are neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), thrombocytopenia (low blood platelet counts), hyperglycaemia (high blood glucose levels), hypokalaemia (low blood potassium levels), paraesthesia (unusual sensations like pins and needles), pleuritic pain (chest pain), dyspnoea (difficulty breathing), bone pain, arthralgia (joint pain), pyrexia (fever), fatigue (tiredness), prolonged QT interval on an electrocardiogram (an alteration of the electrical activity of the heart), and increased levels of alanine aminotransferase and aspartate aminotransferase (liver enzymes). For the full list of all side effects reported with Trisenox, see the Package Leaflet.

Trisenox should not be used in people who may be hypersensitive (allergic) to arsenic trioxide or any of the other ingredients. Because arsenic trioxide can affect the heart, patients receiving Trisenox should be closely monitored, and should have electrocardiograms before and during treatment.

Why has it been approved?

The CHMP decided that Trisenox’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Trisenox was originally authorised under ‘exceptional circumstances’, because, as the disease is rare, limited information was available at the time of approval. As the company had supplied the additional information requested, the ‘exceptional circumstances’ ended on 10 August 2010.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union for Trisenox on 5 March 2002. The marketing authorisation holder is Cephalon Europe. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Trisenox, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

The summary of the opinion of the Committee for Orphan Medicinal Products for Trisenox is available here.

This summary was last updated in 06-2010.

↑ back to table of contents ↑
 

Name

 

TRISENOX 1 mg/ml, concentrate for solution for infusion

 

Composition

 

One ml of TRISENOX contains 1 mg of Arsenic trioxide

For a full list of excipients, see section 6.1

 

Pharmaceutical Form

 

Concentrate for solution for infusion
Sterile, clear, colourless, aqueous solution.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇TRISENOX Solution for infusion 下一篇Valdoxan 25 mg compresse rivest..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位